This study is for people with ALS, a disease that causes muscle weakness. The research looks at a drug called MN-166 (Ibudilast) for one year, with an extra six months where everyone gets the drug. ALS is short for Amyotrophic Lateral Sclerosis, a condition where nerve cells die over time. The study has two parts: a double-blind phase where neither the doctors nor the patients know who gets the real drug or a placebo (a fake pill that looks like the real one, but has no medicine). After one year, everyone can choose to get MN-166 for six more months.

To join, you must be 18 to 80 years old with ALS symptoms for no more than 18 months. You should not have serious liver problems or certain mental health issues. The study will last up to 18 months, including a 30-day screening period.

• Length: 18 months total, with 12 months double-blind and 6 months open-label.
• Visits: Regular check-ups and tests over 18 months.
• Risks: Potential side effects from MN-166, plus common study risks like blood draws.